Fulcrum Therapeutics, Inc. Common Stock

Fulcrum Therapeutics, Inc. Common Stock

FULC Stock Report Card





Score: 10/100


FULC returned -61.47% in the last 12 months. Based on the other stocks in its sector with an average return of -6.24%, its performance is below average giving it a grade of 10 of 100.


Score: 67/100


FULC had a bullish sentiment score of 67.48% across Twitter and StockTwits over the last 12 months. It had an average of 6.96 posts, 0.30 comments, and 1.44 likes per day.


Score: 25/100


FULC receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.


Score: 10/100


FULC has missed earnings 6 times in the last 20 quarters.


Score: 10/100


Out of the last 20 quarters, FULC has had 0 profitable quarters and has increased their profits year over year on 0 of them.


Score: 48/100


FULC has had a lower than average amount of volatility over the last 12 months giving it a grade of 48 of 100.

Fulcrum Therapeutics, Inc. Common Stock Summary

Nasdaq / FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
pluto logo
Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.